Sign up
Pharma Capital

Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack
cancer cell
The article was published online earlier this month and will be in next month’s print edition of Journal of Immunology

A peer-reviewed publication has given backing to a cancer immunotherapy platform developed by PDS Biotechnology Corporation (NASDAQ:PDSB) – one of Netscientific PLC’s (LON:NSCI) portfolio companies.

The article, published online earlier this month in the Journal of Immunology, describes how the Versamune platform recruits and activates T-cells.

READ: Netscientific soars as it sells stakes in Vortex and Wanda

T-cells are responsible for identifying and attacking cancer cells while at the same time making them more susceptible to T-cell attack.

A phase II study of PDS0101 – the lead drug from the Versamune platform – in combination with Merck’s Keytruda in head and neck cancer patients is due to kick off later this year.

Similar studies testing PDS0101 in advanced HPV-associated cancers and on its own in cervical dysplasia are also planned.

Shares in Netscientific, which owns 8.15% of PDS’s stock, rose 16.5% to 9.03p in late-afternoon trading on Thursday.

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.